SLC5A2 and kidney disorder: More recently, evidence has begun to emerge supporting a renoprotective benefit of sodium-glucose cotransporter 2 (SGLT2) inhibitor therapy and this, together with RAS-blockade, probably represents current best care for most patients with Type 2 diabetes and kidney disease.